https://allsci.com/news/debt-financing/intellia-debt-facility-funding-secures-usd-400m/ AllScien 2026-09-04T17:07:54.286470Z Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch https://allsci.com/news/regulatory/ace723-fda-clearance-hepatocellular-carcinoma/ AllScien 2026-09-04T16:30:51.466151Z Acepodia wins FDA clearance for dual-payload GPC3 ADC in liver cancer https://allsci.com/news/venture-financing/neushen-therapeutics-funding-raises-usd-80m-to/ AllScien 2026-09-04T16:21:52.761922Z NeuShen lands USD 80m+ Series B for CNS expansion https://allsci.com/news/clinical-trials/sirna-therapy-hae-argos-cuts-attack-rates-8396-in/ AllScien 2026-09-04T16:06:54.052319Z Argo's siRNA therapy cuts HAE attack rates 83–96% in small Phase II study https://allsci.com/news/clinical-trials/zorevunersen-dravet-syndrome-sustains-seizure/ AllScien 2026-09-04T15:41:17.992673Z Stoke, Biogen report four-year durability for Dravet therapy zorevunersen https://allsci.com/news/clinical-trials/oral-glp-1-agonist-innovent-launches-phase-trial/ AllScien 2026-09-04T15:40:16.839441Z Innovent takes once-weekly oral GLP-1 into Phase I https://allsci.com/news/debt-financing/dimerix-funding-kidney-disease-trial-secures-aud/ AllScien 2026-09-04T13:56:20.443867Z Dimerix secures AUD 34m non-dilutive funding through Phase III kidney disease trial readout https://allsci.com/news/regulatory-pathways/botanical-drug-development-fda-requests-public/ AllScien 2026-09-04T13:32:53.007192Z FDA requests public input on botanical drug product development pathways